Last updated: 17 June 2021 at 5:27pm EST

Mark Edwards Net Worth




The estimated Net Worth of Mark G Edwards is at least $285 Thousand dollars as of 12 November 2019. Mr. Edwards owns over 25,000 units of Acelrx Pharmaceuticals Inc stock worth over $209,625 and over the last 13 years he sold ACRX stock worth over $0. In addition, he makes $75,004 as Independent Director at Acelrx Pharmaceuticals Inc.

Mr. Edwards ACRX stock SEC Form 4 insiders trading

Mark has made over 13 trades of the Acelrx Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of ACRX stock worth $44,500 on 12 November 2019.

The largest trade he's ever made was buying 40,000 units of Acelrx Pharmaceuticals Inc stock on 7 May 2015 worth over $125,200. On average, Mark trades about 9,600 units every 117 days since 2011. As of 12 November 2019 he still owns at least 243,750 units of Acelrx Pharmaceuticals Inc stock.

You can see the complete history of Mr. Edwards stock trades at the bottom of the page.





Mark Edwards biography

Mark G. Edwards serves as Independent Director of the Company. Mr. Edwards is Managing Director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. Since February 2017, Mr. Edwards has also served on the board of directors of Scripps Research Institute, a non-profit medical research facility. From July 2008 until December 2010, he was Managing Director and a Principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu, an audit and financial consulting services firm. Mr. Edwards was previously the Managing Director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California, from 1988 until the sale of Recap to Deloitte in 2008. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation, a biotechnology company. He received his B.A. and M.B.A. degrees from Stanford University. Mr. Edwards’ financial and business expertise, including his background as a business advisor to pharmaceutical and biotechnology companies, provides him with the qualifications and skills to serve as a director.

What is the salary of Mark Edwards?

As the Independent Director of Acelrx Pharmaceuticals Inc, the total compensation of Mark Edwards at Acelrx Pharmaceuticals Inc is $75,004. There are 9 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.



How old is Mark Edwards?

Mark Edwards is 62, he's been the Independent Director of Acelrx Pharmaceuticals Inc since 2011. There are 4 older and 9 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.

What's Mark Edwards's mailing address?

Mark's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 25821 INDUSTRIAL BLVD., SUITE 400, HAYWARD, CA, 94545.

Insiders trading at Acelrx Pharmaceuticals Inc

Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp..., and Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.



What does Acelrx Pharmaceuticals Inc do?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v



What does Acelrx Pharmaceuticals Inc's logo look like?

Acelrx Pharmaceuticals Inc logo

Complete history of Mr. Edwards stock trades at Acelrx Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
12 Nov 2019 Mark G Edwards
Director
Buy 25,000 $1.78 $44,500
12 Nov 2019
243,750
23 Aug 2019 Mark G Edwards
Director
Buy 15,000 $2.19 $32,850
23 Aug 2019
218,750
12 Mar 2019 Mark G Edwards
Director
Buy 19,000 $2.99 $56,810
12 Mar 2019
200,000
15 Nov 2018 Mark G Edwards
Director
Buy 20,700 $2.82 $58,374
15 Nov 2018
181,000
7 Aug 2018 Mark G Edwards
Director
Buy 5,300 $2.84 $15,052
7 Aug 2018
160,300
1 Jun 2018 Mark G Edwards
Director
Buy 5,000 $3.35 $16,750
1 Jun 2018
155,000
14 Nov 2017 Mark G Edwards
Director
Buy 30,000 $1.90 $57,000
14 Nov 2017
150,000
22 Aug 2017 Mark G Edwards
Director
Buy 5,000 $3.02 $15,100
22 Aug 2017
120,000
10 May 2016 Mark G Edwards
Director
Buy 15,000 $3.15 $47,250
10 May 2016
115,000
7 May 2015 Mark G Edwards
Director
Buy 40,000 $3.13 $125,200
7 May 2015
100,000
6 Jun 2013 Mark G Edwards
Director
Buy 10,000 $8.10 $81,000
6 Jun 2013
60,000
1 Dec 2011 Mark G Edwards
Director
Buy 10,000 $2.79 $27,900
1 Dec 2011
50,000
14 Nov 2011 Mark G Edwards
Director
Buy 40,000 $2.90 $116,000
14 Nov 2011
40,000


Acelrx Pharmaceuticals Inc executives and stock owners

Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: